|
Turkey Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Turkey Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Turkey.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Turkish pharmaceutical and healthcare industry.
Competitive intelligence, Turkish pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Turkish market.
The Turkey Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Turkey Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Turkish pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Turkey to test other views – a key input for successful budgeting and strategic business planning in the Turkish pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Turkish Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Turkey.
- Exploit The Latest Competitive Turkish Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Turkey.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Turkey Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - SWOT Analysis |
| Turkey Pharmaceuticals And Healthcare Industry SWOT |
| Turkey Political SWOT |
| Turkey Economic SWOT |
| Turkey Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Rating |
| Regional Pharma Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Turkey – Market Summary |
| Regulatory Regime |
| Intellectual Property Regime |
| Intellectual Property Shortcomings |
| Counterfeit Drugs |
| Pricing Regime |
| Table: Turkish Pharmacy And Wholesale Mark-Ups |
| Reimbursement Regime |
Chapter - Sector Developments |
| Epidemiology |
| Table: Disease Burden In CEE |
| Healthcare Sector |
| Healthcare Expenditure |
| Healthcare Sector Reforms |
| Health Insurance |
| Private Healthcare Sector |
| Pharmaceutical Sector |
| Pharmaceutical Retail And Distribution |
| Recent Pharmaceutical Sector Developments |
| International Co-operation |
| Research And Development Sector |
| Table: Turkey's New R&D Law |
| Medical Devices |
| Recent Medical Devices Industry Developments |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Turkey – Drug Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Turkey – Healthcare Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Turkey – Economic Activity |
| Prescription Market Forecast |
| Table: Turkey – Prescription Market Indicators, 2004-2013 (TRYmn unless otherwise stated) |
| OTC Market Forecast |
| Table: Turkey – OTC Market Indicators, 2004-2013 (TRYmn unless otherwise stated) |
| Patented Drug Market Forecast |
| Table: Turkey – Patented Market Indicators, 2004-2013 |
| Generic Drug Market Forecast |
| Table: Turkey – Generics Market Indicators, 2004-2013 |
| Export/Import Market Forecasts |
| Table: Turkey – Pharmaceutical Trade Indicators, 2004-2013 (US$mn) |
| Other Healthcare Data |
| Table: Turkey – Other Healthcare Indicators, 2004-2013 |
Chapter - Competitive Landscape |
| Table: Top 10 Pharmaceutical Companies In Turkey By Market Share, MAT July 2008 |
Chapter - Company Profiles |
| Novartis |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Pfizer |
| Roche |
| AstraZeneca |
| Bayer |
| Merck & Co |
| Indigenous Companies |
| Abdi Ibrahim |
| Eczacibasi Pharmaceuticals |
| Sanovel Pharmaceuticals |
| EastPharma (formerly Deva Holding) |
| Actavis (formerly Fako) |
| Biomeks |
Chapter - Country Snapshot: Turkey Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Turkey Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Outside the BRIC (Brazil, Russia, India, China) states, Turkey is considered one of the key growth pharmaceutical markets globally. Growth has been rapid in recent years, with per capita spending reaching US$159 in 2008, a similar level to other emerging countries in Eastern Europe. The country’s large, ageing and increasingly urbanised population, means both demand and access to medicines should increase in the future. Over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter (OTC) medicines, will increase from US$11.3bn to US$19.5bn, representing a compound annual growth rate (CAGR) of 11.6%.
Despite positive market and environmental dynamics, Turkey ranks only fifth in BMI’s Pharmaceutical Business Environment Rankings for Q209. The core reasoning behind this is the still considerable risks present in operating in the country. A negative regulatory climate is a key drawback for multinationals. Delays in bringing products to market, unfavourable pricing regimes and poorly enforced intellectual property regulations are some of the problems associated with operating in Turkey at present. Furthermore, policy continuity, bureaucracy and the legal framework remain key concerns.
Legislation for the creation of a universal healthcare system was enforced in late 2008. The universal health insurance scheme includes: compulsory participation with income-based contributions; subsidies or free coverage for the disadvantaged or those under 18 years of age; the use of public/private partnerships (PPPs) for providing care; and differentiated co-payment rates between primary, secondary and tertiary care. The implementation of this throughout 2009 will give a key indicator as to the potential for increased pharmaceutical and health expenditure.
Perceived opportunities to capitalise on growing healthcare expenditure have led to multinational investment in private healthcare facilities in recent years. However, credit-driven investments – in an increasingly tight lending environment – along with caps on top-up charges for regular services, appear to have resulted in the accumulation of large levels of debt. While the longer term outlook for private hospitals is positive, up to US$3bn is said to be owed by facilities, which could lead to significant difficulties for some operations in 2009.
BMI’s Burden of Disease Database (BoDD) reveals that development of the healthcare service is having a positive effect on the country’s disease profile. Disability-adjusted life years (DALYs) lost to all diseases and injuries are steadily declining in the country. In 2008 Turkey was placed 66th globally in terms of per capita DALYs. The obvious trend seen by improved access to care is the decreasing burden of communicable diseases, which we forecast to fall by 46% over 2008-2030. Meanwhile as the country becomes increasingly Westernised, non-communicable diseases will continue to increase. This will be reflected in pharmaceutical sales, with cardiovascular treatments rising and anti-infectives falling through to 2013.
|
Turkey Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |